期刊文献+

咪唑立宾结晶工艺研究

Crystallization Process of Mizoribine
下载PDF
导出
摘要 对咪唑立宾的结晶工艺进行优化,探究了抗溶剂种类、溶液初始浓度、抗溶剂滴加速度及抗溶剂加量对咪唑立宾结晶纯度、堆密度、收率和产品稳定性的影响。确定最佳结晶工艺为:以乙醇为抗溶剂、溶液初始浓度0.7 g·mL^-1、抗溶剂滴加速度5 BV·h^-1、抗溶剂加量为咪唑立宾水溶液体积的12倍(12 BV)。该结晶工艺所得产品纯度高、杂质少、堆密度较大、稳定性好,适合工业化生产,有利于长期储存和制剂分装。 We optimized the crystallization process of Mizoribine,and investigated the effects of anti-solvent types,initial concentration of solution,dropping rate of anti-solvent,and anti-solvent dosage on the purity,bulk density,yield,and stability of Mizoribine crystal.The optimal crystallization process is determined as follows:ethanol is used as the anti-solvent,the initial concentration of solution is 0.7 g·mL^-1,the dropping rate of anti-solvent is 5 BV·h^-1,and the anti-solvent dosage is 12 times(12 BV)the volume of Mizoribine aqueous solution.The obtained product has high purity,low impurity,large bulk density,and good stability,and this crystallization process is suitable for industrial production and is beneficial to long-term storage and preparation packaging.
作者 程曜峰 冷凤 孙丙林 张炜 张雪霞 CHENG Yaofeng;LENG Feng;SUN Binglin;ZHANG Wei;ZHANG Xuexia(NCPC New Drug Research & Development Co.,Ltd.,National Engineering Research Center of Microbial Medicine,Hebei Industry Microbial Metabolic Engineering & Technology Research Center,Shijiazhuang 050015,China;NCPC Huasheng Co.,Ltd.,Shijiazhuang 050015,China)
出处 《化学与生物工程》 CAS 2020年第11期61-63,共3页 Chemistry & Bioengineering
基金 河北省科技研发平台建设专项(199676154H)。
关键词 咪唑立宾 结晶 稳定性 堆密度 Mizoribine crystallization stability bulk density
  • 相关文献

参考文献5

二级参考文献42

  • 1王长希,刘龙山,陈立中,吴培根,费继光,邱江,邓素雄,郑克立,纪玉莲,朱兰英,沈清瑞,何晓顺.雷帕霉素治疗肾移植术后肿瘤八例[J].中华器官移植杂志,2005,26(5):278-279. 被引量:8
  • 2钱叶勇,石炳毅,梁春泉.肾移植病人抗排斥反应治疗方案中应用雷公藤多甙的疗效观察[J].中华泌尿外科杂志,1995,16(5):268-269. 被引量:10
  • 3Xu X, Shen J, Mall JW, et al. In vitro and in vivo antitumor activity of a novel immunomodulatory drug, leflunomide: mechanisms of action. Biochem Pharmacol, 1999,58:1405-1413.
  • 4Penn I. Occurrence of cancers in immunosuppressed organ transplant recipients. Clin Transpl, 1998,12:147-158.
  • 5Aoki M, Blazek E, Vogt PK. A role of the kinase mTOR in cellular transformation induced by the oncoproteins P3k and Akt.Proc Natl Acad Sci USA, 2001,98:136-141.
  • 6Majewski M, Korecka M, Joergensen J, et al. Immunosuppressire TOR kinase inhibitor everolimus (RAD) suppresses growth of cells derived from posttransplant lymphoproliferative disorder at allograft-protecting doses. Transplantation, 2003, 75:1710-1717.
  • 7Guba M, von Breitenbuch P, Steinbauer M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis:involvement of vascular endothelial growth factor. Nat Med,2002, 8:128-135.
  • 8Luan FL, Ding R, Sharma VK, et al. Raparaycin is an effective inhibitor of human renal cancer metastasis. Kidney Int, 2003,63:917-926.
  • 9Koehl G, Guba M, Seeliger H, et al. Rapamycin treatment at immunosuppressive doses affects tumor blood vessel circulation.Transplant Proc, 2003,35:2135-2136.
  • 10Luan FL, Hojo M, Maluccio M, et al. Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy. Transplantation ,2002, 73:1565-1572.

共引文献266

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部